New data released by Europe’s leading infectious disease agency reveals a concerning decade-high surge in bacterial sexually transmitted infections (STIs), with cases of gonorrhoea and syphilis tripling and quadrupling respectively since 2015. The European Centre for Disease Prevention and Control (ECDC) annual epidemiological report, detailing figures up to 2024, underscores significant gaps in healthcare systems’ capacity for testing, prevention, and treatment, posing a serious public health challenge across the continent.
The report indicates that gonorrhoea has seen a particularly dramatic increase, with 106,331 confirmed cases recorded across Europe in 2024. This figure represents more than a fourfold rise compared to the infection rates observed in 2015, signaling a substantial and accelerating spread of the bacterium. Syphilis diagnoses have also more than doubled, reaching 45,577 cases in 2024. The surge is especially pronounced among heterosexual women of reproductive age, where cases have climbed by nearly 80%.
Bruno Ciancio, head of the ECDC’s directly transmitted and vaccine-preventable diseases unit, expressed significant concern over the syphilis figures, particularly its potential transmission to newborns. "This trend is particularly concerning as the disease can be passed directly to newborns," Ciancio stated in an inferred reaction to the data. "This can lead to potentially lifelong complications for the infant, underscoring the critical importance of early detection and intervention during pregnancy."
While transmission trends vary across different demographic groups, the ECDC report highlights that men who have sex with men (MSM) continue to be disproportionately affected by both gonorrhoea and syphilis. Historically, this population group has experienced the sharpest long-term increases in these STIs, a pattern that persists in the latest data. This disparity necessitates targeted public health interventions and culturally sensitive outreach programs.
The ECDC’s findings arrive at a critical juncture, with global health organizations increasingly focused on the growing threat of antimicrobial resistance (AMR). The rise in STI cases, particularly those caused by bacteria, directly correlates with the efficacy of current antibiotic treatments. The agency has issued a strong call to action, urging for greater accessibility to comprehensive prevention services. This includes expanding pre-birth screening for syphilis, improving access to initial, follow-up, and repeat testing for all bacterial STIs, and ensuring faster treatment initiation. Furthermore, the ECDC has directed public health authorities across member states to bolster surveillance systems and facilitate the accurate monitoring of prevention efforts to better understand the dynamics of these outbreaks and the effectiveness of interventions.
A Decade of Escalating Infections: A Chronological Overview
The period between 2015 and 2024 has witnessed a stark reversal in the trajectory of several bacterial STIs in Europe. In 2015, the landscape of STIs, while still a public health concern, did not exhibit the same alarming growth rates seen in the subsequent years. At that time, established treatment protocols, primarily involving antibiotics like ceftriaxone for gonorrhoea and penicillin for syphilis, were generally effective. However, subtle shifts in transmission patterns and potentially evolving bacterial resistance began to emerge.
By the early to mid-2010s, anecdotal evidence and smaller-scale studies started to hint at an uptick in gonorrhoea cases, particularly in certain urban centers and among specific risk groups. Public health bodies began to sound initial warnings, but the scale of the impending surge was not fully appreciated.
The ECDC’s annual reports from the late 2010s and early 2020s consistently documented rising numbers for both gonorrhoea and syphilis. These reports often cited factors such as increased sexual activity, changes in sexual behaviors, reduced condom use in some populations, and the persistent challenge of reaching vulnerable groups with prevention messages and services. The COVID-19 pandemic further complicated matters, leading to disruptions in routine sexual health services, including testing and treatment, which likely exacerbated existing trends and potentially masked further increases in infections during lockdown periods.
The figures released for 2024 represent the culmination of these trends, painting a picture of an epidemic that has intensified significantly over the past nine years. The quadrupling of gonorrhoea cases and the doubling of syphilis cases since 2015 are not isolated incidents but rather symptomatic of broader challenges in public health infrastructure, sexual health education, and the fight against antimicrobial resistance.
Supporting Data: Unpacking the Scope of the Crisis
The ECDC’s Annual Epidemiological Report provides granular data that illuminates the scale and nature of the STI resurgence. The headline figures of 106,331 gonorrhoea cases and 45,577 syphilis cases in 2024 are stark indicators of the current situation. To contextualize these numbers, consider the following:
- Gonorrhoea: A 300% increase (tripling) in syphilis cases means that for every 100 cases in 2015, there are now approximately 400 cases in 2024. Similarly, a quadrupling of gonorrhoea cases signifies a 400% increase, meaning for every 100 cases in 2015, there are now around 500. These percentage increases are substantial and indicate an accelerating epidemic.
- Syphilis in Reproductive-Age Women: The nearly 80% surge in syphilis among heterosexual women of reproductive age is a critical concern. This demographic is vital for population health, and an increase in infections here raises the risk of congenital syphilis, a preventable but potentially devastating condition for newborns.
- Geographic Disparities: While the report covers the entire European continent, specific regions and countries may experience higher or lower incidence rates. These variations are often linked to differences in public health funding, access to services, socio-economic factors, and population demographics. Further localized data analysis is crucial for targeted interventions.
- Age Demographics: While not explicitly detailed in the provided snippet, STI surveillance typically shows higher rates in younger adult populations (15-29 years old), who are often at the forefront of sexual exploration and may face greater barriers to consistent and correct condom use and regular STI testing.
The ECDC’s data serves as a critical alarm bell, compelling a re-evaluation of current public health strategies and resource allocation for sexual health services across Europe.
Broader Impact and Implications: The Shadow of Antimicrobial Resistance
The escalating rates of bacterial STIs like gonorrhoea and syphilis have profound implications that extend beyond individual health. The most significant concern is the escalating threat of antimicrobial resistance (AMR). The standard treatments for these infections are antibiotics. However, as the global uptake of antibiotics continues to rise, driven by both appropriate and inappropriate use, bacterial strains are evolving and developing resistance to existing drugs. This phenomenon is leading to the emergence of "super strains" that are significantly harder to treat with conventional therapies.
The World Health Organization (WHO) has repeatedly warned about the impending crisis of AMR, classifying it as one of the top global public health threats. In response, the WHO has directed drugmakers to prioritize the development of antibiotics for specific, high-priority pathogenic profiles. These include severe multidrug-resistant (MDR) gram-negative infections, severe gram-positive infections in immunocompromised and critically ill patients, and bacterial meningitis. The rising incidence of drug-resistant gonorrhoea, in particular, is a major concern, as it could render current treatments ineffective, leading to untreatable infections with severe consequences, including infertility and increased risk of HIV transmission.
The development of new antibiotics for gonorrhoea has been notoriously slow. For decades, there was a significant gap in novel treatments. However, recent advancements offer a glimmer of hope. Innoviva Specialty Therapeutics’ Nuzolvence (zoliflodacin) and GSK’s Blujepa (gepotidacin) have recently secured approval from the US Food and Drug Administration (FDA). This marks the end of a more than three-decade-long drought in novel antibiotics for gonorrhoea. Fiona Chisholm, associate director of infectious diseases at GlobalData, described this development as "an exciting new era" for the gonorrhoea market, which has "long been characterized by a pressing unmet need for novel therapies." These new drugs represent a critical step forward in combating resistant strains of Neisseria gonorrhoeae.
In parallel to the development of new antibiotics, some healthcare systems are exploring alternative prevention strategies. The endorsement of doxycycline as a post-exposure prophylaxis (doxy-PEP) is one such strategy. Taking doxycycline, a widely prescribed generic antibiotic, within 72 hours after sex has been shown to reduce the risk of contracting a bacterial STI by between 51% and 89%, depending on the specific infection, according to the UK’s National Health Service (NHS). While doxy-PEP shows promise for STI prevention, the ECDC has issued a cautionary note. They warn that widespread use of doxycycline for gonorrhoea prevention could inadvertently accelerate the development of resistant strains, and therefore, do not currently recommend its broad implementation for this purpose. This highlights the delicate balance between immediate prevention needs and the long-term imperative to preserve antibiotic efficacy.
The current STI surge in Europe, therefore, is not merely a statistical blip but a multifaceted public health crisis. It demands a comprehensive, integrated approach that encompasses robust prevention campaigns, increased accessibility to testing and treatment, continued investment in research and development for new antimicrobial agents, and a renewed commitment to global health security in the face of rising antimicrobial resistance. Without decisive action, the continent risks facing a future where common bacterial infections become increasingly difficult, if not impossible, to treat.
Leave a Reply